Pharma goes all in on cancer treatments

A new EvaluatePharma report reiterates just how heavily the pharmaceutical industry is banking on oncology.

Why it matters: The report also adds more evidence that drugs are getting more costly, and these costs will increasingly be driven by medicines with little to no competition.

• Global drug sales are expected to reach $1.18 trillion in 2024, compared to $843 billion in 2019, and $239 billion of the 2024 total is expected to be spent on orphan drugs that treat small populations.

Go deeper: The drug pricing debate is stuck in the past